サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1487571

バイオエンジニアードタンパク薬剤市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測

Bioengineered Protein Drugs Market (Disease Condition: Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Hematopoiesis, CVD, Neurodegenerative, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2034

出版日
ページ情報
英文 202 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.64円
バイオエンジニアードタンパク薬剤市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測
出版日: 2024年04月15日
発行: Transparency Market Research
ページ情報: 英文 202 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

バイオエンジニアードタンパク薬剤市場- 調査範囲

TMRの世界バイオエンジニアードタンパク薬剤市場に関する調査レポートは、2024年から2034年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界のバイオエンジニアードタンパク薬剤市場の収益と予測を提供しています。また、2024年から2034年までの世界のバイオエンジニアードタンパク薬剤市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、生物工学タンパク質医薬品市場を理解しました。

市場スナップショット
2023年の市場規模 3,471億米ドル
2034年の市場価値 6,727億米ドル
CAGR 6.2%

当レポートでは、世界のバイオエンジニアードタンパク薬剤市場の競合情勢について調査しています。世界のバイオエンジニアードタンパク薬剤市場で事業を展開する主要企業が特定され、各企業がさまざまな属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTは、本レポートでプロファイリングされた世界のバイオエンジニアードタンパク薬剤市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：市場

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 市場力学
  • 市場分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品・ブランド分析
  • 主要M&A
  • COVID-19パンデミックの産業への影響

第6章 世界市場分析と予測：薬剤タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：薬剤タイプ別、2020-2034年
    • モノクローナル抗体
      • ヒュミラ
      • リツキサン
      • アバスチン
      • ハーセプチン
      • レミケード
      • ルセンティス
      • エンブレル
      • シナジス
      • その他
    • 治療用タンパク質
      • ホルモン
      • サイトカイン
        • ノイポゲン
        • ノイラスタ
        • インターフェロンアルファ
        • エリスロポエチンアルファ
        • インターロイキン
        • その他
    • 血液因子
    • 酵素療法
      • 全身酵素療法
      • 消化酵素療法
    • 血栓溶解薬
      • tPA
      • ストレプトキナーゼ
      • ウロキナーゼ
    • ワクチン
  • 市場魅力度分析：薬剤タイプ別

第7章 世界市場分析・予測：疾患別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：疾患別、2020-2034年
    • がん
    • 糖尿病
    • 自己免疫疾患
    • 感染症
    • 造血
    • CVD
    • 神経変性
    • その他
  • 市場魅力度分析：病態別

第8章 世界市場分析・予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：エンドユーザー別、2020-2034年
    • 製薬企業およびバイオテクノロジー企業
    • CRO
    • 研究機関
  • 市場魅力度分析：エンドユーザー別

第9章 世界市場分析・予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020-2034年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と展望

第14章 中東・アフリカ市場の分析と展望

第15章 競合情勢

  • 市場競合マトリックス（企業階層別・企業規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • Abbott
    • Amgen Inc.
    • Bayer AG
    • Biocon
    • Dr. Reddy's Laboratories
    • Lilly
    • F. Hoffmann-La Roche Ltd.
    • Fresenius Kabi AG
    • GSK
    • Janssen Global Services
    • Merck & Co., Inc.
    • Novartis AG
    • Panacea Biotec
    • ProBioGen AG
    • Reliance Life Science
    • Sanofi
図表

List of Tables

  • Table 01: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 02: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 03: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 04: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 05: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 06: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 07: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 08: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 09: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 11: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 12: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 13: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 15: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 16: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 17: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 19: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 20: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 21: Middle East & Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 23: Middle East & Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 24: Middle East & Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Bioengineered Protein Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Bioengineered Protein Drugs Market Revenue (US$ Mn), by Drug Type, 2023
  • Figure 03: Global Bioengineered Protein Drugs Market Value Share, by Drug Type, 2023
  • Figure 04: Global Bioengineered Protein Drugs Market Revenue (US$ Mn), by Disease Condition, 2023
  • Figure 05: Global Bioengineered Protein Drugs Market Value Share, by Disease Condition, 2023
  • Figure 06: Global Bioengineered Protein Drugs Market Revenue (US$ Mn), by End-user, 2023
  • Figure 07: Global Bioengineered Protein Drugs Market Value Share, by End-user, 2023
  • Figure 08: Global Bioengineered Protein Drugs Market Value Share, by Region, 2023
  • Figure 09: Global Bioengineered Protein Drugs Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 10: Global Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 11: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 13: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 14: Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 15: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 16: Global Bioengineered Protein Drugs Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Bioengineered Protein Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Bioengineered Protein Drugs Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 22: North America Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 23: North America Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 24: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 26:North America Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 27: Europe Bioengineered Protein Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Bioengineered Protein Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 31: Europe Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 32: Europe Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 33: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 35: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 36: Asia Pacific Bioengineered Protein Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 40: Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 41: Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 42: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 44: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 45: Latin America Bioengineered Protein Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Bioengineered Protein Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 49: Latin America Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 50: Latin America Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 53: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 54: Middle East & Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Bioengineered Protein Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 58: Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 59: Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 60: Middle East & Africa Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 62: Middle East & Africa Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
目次
Product Code: TMRGL8188

Bioengineered Protein Drugs Market - Scope of Report

TMR's report on the global bioengineered protein drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global bioengineered protein drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global bioengineered protein drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the bioengineered protein drugs market.

Market Snapshot
Market Value in 2023US$ 347.1 Bn
Market Value in 2034US$ 672.7 Bn
CAGR6.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global bioengineered protein drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global bioengineered protein drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global bioengineered protein drugs market.

The report delves into the competitive landscape of the global bioengineered protein drugs market. Key players operating in the global bioengineered protein drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global bioengineered protein drugs market profiled in this report.

Key Questions Answered in Global bioengineered protein drugs Market Report:

  • What is the sales/revenue generated by bioengineered protein drugs across all regions during the forecast period?
  • What are the opportunities in the global bioengineered protein drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Bioengineered Protein Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global bioengineered protein drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global bioengineered protein drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global bioengineered protein drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Bioengineered Protein Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Bioengineered Protein Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2020-2034
    • 6.3.1. Monoclonal Antibodies
      • 6.3.1.1. Humira
      • 6.3.1.2. Rituxan
      • 6.3.1.3. Avastin
      • 6.3.1.4. Herceptin
      • 6.3.1.5. Remicade
      • 6.3.1.6. Lucentis
      • 6.3.1.7. Enbrel
      • 6.3.1.8. Synazis
      • 6.3.1.9. Others
    • 6.3.2. Therapeutic Proteins
      • 6.3.2.1. Hormones
      • 6.3.2.2. Cytokines
        • 6.3.2.2.1. Neupogen
        • 6.3.2.2.2. Neulasta
        • 6.3.2.2.3. Interferon Alpha
        • 6.3.2.2.4. Erythropoietin Alpha
        • 6.3.2.2.5. Interleukin
        • 6.3.2.2.6. Others
    • 6.3.3. Blood Factor
    • 6.3.4. Enzyme Therapy
      • 6.3.4.1. Systemic Enzyme Therapy
      • 6.3.4.2. Digestive Enzyme Therapy
    • 6.3.5. Thrombolytics
      • 6.3.5.1. tPA
      • 6.3.5.2. Streptokinase
      • 6.3.5.3. Urokinase
    • 6.3.6. Vaccines
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Disease Condition

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Condition, 2020-2034
    • 7.3.1. Cancer
    • 7.3.2. Diabetes
    • 7.3.3. Autoimmune Disorder
    • 7.3.4. Infectious Disease
    • 7.3.5. Hematopoiesis
    • 7.3.6. CVD
    • 7.3.7. Neurodegenerative
    • 7.3.8. Others
  • 7.4. Market Attractiveness Analysis, by Disease Condition

8. Global Bioengineered Protein Drugs Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020-2034
    • 8.3.1. Pharma and Biotech Companies
    • 8.3.2. CROs
    • 8.3.3. Research Institutes
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Bioengineered Protein Drugs Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Type, 2020-2034
    • 10.3.1. Monoclonal Antibodies
      • 10.3.1.1. Humira
      • 10.3.1.2. Rituxan
      • 10.3.1.3. Avastin
      • 10.3.1.4. Herceptin
      • 10.3.1.5. Remicade
      • 10.3.1.6. Lucentis
      • 10.3.1.7. Enbrel
      • 10.3.1.8. Synazis
      • 10.3.1.9. Others
    • 10.3.2. Therapeutic Proteins
      • 10.3.2.1. Hormones
      • 10.3.2.2. Cytokines
        • 10.3.2.2.1. Neupogen
        • 10.3.2.2.2. Neulasta
        • 10.3.2.2.3. Interferon Alpha
        • 10.3.2.2.4. Erythropoietin Alpha
        • 10.3.2.2.5. Interleukin
        • 10.3.2.2.6. Others
    • 10.3.3. Blood Factor
    • 10.3.4. Enzyme Therapy
      • 10.3.4.1. Systemic Enzyme Therapy
      • 10.3.4.2. Digestive Enzyme Therapy
    • 10.3.5. Thrombolytics
      • 10.3.5.1. tPA
      • 10.3.5.2. Streptokinase
      • 10.3.5.3. Urokinase
    • 10.3.6. Vaccines
  • 10.4. Market Value Forecast, by Disease Condition, 2020-2034
    • 10.4.1. Cancer
    • 10.4.2. Diabetes
    • 10.4.3. Autoimmune Disorder
    • 10.4.4. Infectious Disease
    • 10.4.5. Hematopoiesis
    • 10.4.6. CVD
    • 10.4.7. Neurodegenerative
    • 10.4.8. Others
  • 10.5. Market Value Forecast, by End-user, 2020-2034
    • 10.5.1. Pharma and Biotech Companies
    • 10.5.2. CROs
    • 10.5.3. Research Institutes
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Type
    • 10.7.2. By Disease Condition
    • 10.7.3. By End-user
    • 10.7.4. By Country

11. Europe Bioengineered Protein Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Type, 2020-2034
    • 11.3.1. Monoclonal Antibodies
      • 11.3.1.1. Humira
      • 11.3.1.2. Rituxan
      • 11.3.1.3. Avastin
      • 11.3.1.4. Herceptin
      • 11.3.1.5. Remicade
      • 11.3.1.6. Lucentis
      • 11.3.1.7. Enbrel
      • 11.3.1.8. Synazis
      • 11.3.1.9. Others
    • 11.3.2. Therapeutic Proteins
      • 11.3.2.1. Hormones
      • 11.3.2.2. Cytokines
        • 11.3.2.2.1. Neupogen
        • 11.3.2.2.2. Neulasta
        • 11.3.2.2.3. Interferon Alpha
        • 11.3.2.2.4. Erythropoietin Alpha
        • 11.3.2.2.5. Interleukin
        • 11.3.2.2.6. Others
    • 11.3.3. Blood Factor
    • 11.3.4. Enzyme Therapy
      • 11.3.4.1. Systemic Enzyme Therapy
      • 11.3.4.2. Digestive Enzyme Therapy
    • 11.3.5. Thrombolytics
      • 11.3.5.1. tPA
      • 11.3.5.2. Streptokinase
      • 11.3.5.3. Urokinase
    • 11.3.6. Vaccines
  • 11.4. Market Value Forecast, by Disease Condition, 2020-2034
    • 11.4.1. Cancer
    • 11.4.2. Diabetes
    • 11.4.3. Autoimmune Disorder
    • 11.4.4. Infectious Disease
    • 11.4.5. Hematopoiesis
    • 11.4.6. CVD
    • 11.4.7. Neurodegenerative
    • 11.4.8. Others
  • 11.5. Market Value Forecast, by End-user, 2020-2034
    • 11.5.1. Pharma and Biotech Companies
    • 11.5.2. CROs
    • 11.5.3. Research Institutes
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Type
    • 11.7.2. By Disease Condition
    • 11.7.3. By End-user
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Bioengineered Protein Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Type, 2020-2034
    • 12.3.1. Monoclonal Antibodies
      • 12.3.1.1. Humira
      • 12.3.1.2. Rituxan
      • 12.3.1.3. Avastin
      • 12.3.1.4. Herceptin
      • 12.3.1.5. Remicade
      • 12.3.1.6. Lucentis
      • 12.3.1.7. Enbrel
      • 12.3.1.8. Synazis
      • 12.3.1.9. Others
    • 12.3.2. Therapeutic Proteins
      • 12.3.2.1. Hormones
      • 12.3.2.2. Cytokines
        • 12.3.2.2.1. Neupogen
        • 12.3.2.2.2. Neulasta
        • 12.3.2.2.3. Interferon Alpha
        • 12.3.2.2.4. Erythropoietin Alpha
        • 12.3.2.2.5. Interleukin
        • 12.3.2.2.6. Others
    • 12.3.3. Blood Factor
    • 12.3.4. Enzyme Therapy
      • 12.3.4.1. Systemic Enzyme Therapy
      • 12.3.4.2. Digestive Enzyme Therapy
    • 12.3.5. Thrombolytics
      • 12.3.5.1. tPA
      • 12.3.5.2. Streptokinase
      • 12.3.5.3. Urokinase
    • 12.3.6. Vaccines
  • 12.4. Market Value Forecast, by Disease Condition, 2020-2034
    • 12.4.1. Cancer
    • 12.4.2. Diabetes
    • 12.4.3. Autoimmune Disorder
    • 12.4.4. Infectious Disease
    • 12.4.5. Hematopoiesis
    • 12.4.6. CVD
    • 12.4.7. Neurodegenerative
    • 12.4.8. Others
  • 12.5. Market Value Forecast, by End-user, 2020-2034
    • 12.5.1. Pharma and Biotech Companies
    • 12.5.2. CROs
    • 12.5.3. Research Institutes
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Type
    • 12.7.2. By Disease Condition
    • 12.7.3. By End-user
    • 12.7.4. By Country/Sub-region

13. Latin America Bioengineered Protein Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Type, 2020-2034
    • 13.3.1. Monoclonal Antibodies
      • 13.3.1.1. Humira
      • 13.3.1.2. Rituxan
      • 13.3.1.3. Avastin
      • 13.3.1.4. Herceptin
      • 13.3.1.5. Remicade
      • 13.3.1.6. Lucentis
      • 13.3.1.7. Enbrel
      • 13.3.1.8. Synazis
      • 13.3.1.9. Others
    • 13.3.2. Therapeutic Proteins
      • 13.3.2.1. Hormones
      • 13.3.2.2. Cytokines
        • 13.3.2.2.1. Neupogen
        • 13.3.2.2.2. Neulasta
        • 13.3.2.2.3. Interferon Alpha
        • 13.3.2.2.4. Erythropoietin Alpha
        • 13.3.2.2.5. Interleukin
        • 13.3.2.2.6. Others
    • 13.3.3. Blood Factor
    • 13.3.4. Enzyme Therapy
      • 13.3.4.1. Systemic Enzyme Therapy
      • 13.3.4.2. Digestive Enzyme Therapy
    • 13.3.5. Thrombolytics
      • 13.3.5.1. tPA
      • 13.3.5.2. Streptokinase
      • 13.3.5.3. Urokinase
    • 13.3.6. Vaccines
  • 13.4. Market Value Forecast, by Disease Condition, 2020-2034
    • 13.4.1. Cancer
    • 13.4.2. Diabetes
    • 13.4.3. Autoimmune Disorder
    • 13.4.4. Infectious Disease
    • 13.4.5. Hematopoiesis
    • 13.4.6. CVD
    • 13.4.7. Neurodegenerative
    • 13.4.8. Others
  • 13.5. Market Value Forecast, by End-user, 2020-2034
    • 13.5.1. Pharma and Biotech Companies
    • 13.5.2. CROs
    • 13.5.3. Research Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Type
    • 13.7.2. By Disease Condition
    • 13.7.3. By End-user
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Bioengineered Protein Drugs Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Type, 2020-2034
    • 14.3.1. Monoclonal Antibodies
      • 14.3.1.1. Humira
      • 14.3.1.2. Rituxan
      • 14.3.1.3. Avastin
      • 14.3.1.4. Herceptin
      • 14.3.1.5. Remicade
      • 14.3.1.6. Lucentis
      • 14.3.1.7. Enbrel
      • 14.3.1.8. Synazis
      • 14.3.1.9. Others
    • 14.3.2. Therapeutic Proteins
      • 14.3.2.1. Hormones
      • 14.3.2.2. Cytokines
        • 14.3.2.2.1. Neupogen
        • 14.3.2.2.2. Neulasta
        • 14.3.2.2.3. Interferon Alpha
        • 14.3.2.2.4. Erythropoietin Alpha
        • 14.3.2.2.5. Interleukin
        • 14.3.2.2.6. Others
    • 14.3.3. Blood Factor
    • 14.3.4. Enzyme Therapy
      • 14.3.4.1. Systemic Enzyme Therapy
      • 14.3.4.2. Digestive Enzyme Therapy
    • 14.3.5. Thrombolytics
      • 14.3.5.1. tPA
      • 14.3.5.2. Streptokinase
      • 14.3.5.3. Urokinase
    • 14.3.6. Vaccines
  • 14.4. Market Value Forecast, by Disease Condition, 2020-2034
    • 14.4.1. Cancer
    • 14.4.2. Diabetes
    • 14.4.3. Autoimmune Disorder
    • 14.4.4. Infectious Disease
    • 14.4.5. Hematopoiesis
    • 14.4.6. CVD
    • 14.4.7. Neurodegenerative
    • 14.4.8. Others
  • 14.5. Market Value Forecast, by End-user, 2020-2034
    • 14.5.1. Pharma and Biotech Companies
    • 14.5.2. CROs
    • 14.5.3. Research Institutes
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Type
    • 14.7.2. By Disease Condition
    • 14.7.3. By End-user
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Abbott
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Amgen Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Bayer AG
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Biocon
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Dr. Reddy's Laboratories
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Lilly
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. F. Hoffmann - La Roche Ltd.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Fresenius Kabi AG
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. GSK
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Janssen Global Services
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Merck & Co., Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Novartis AG
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Panacea Biotec
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. ProBioGen AG
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Product Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview
    • 15.3.15. Reliance Life Science
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Product Portfolio
      • 15.3.15.3. SWOT Analysis
      • 15.3.15.4. Financial Overview
      • 15.3.15.5. Strategic Overview
    • 15.3.16. Sanofi
      • 15.3.16.1. Company Overview
      • 15.3.16.2. Product Portfolio
      • 15.3.16.3. SWOT Analysis
      • 15.3.16.4. Financial Overview
      • 15.3.16.5. Strategic Overview